Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early-phase Schizophrenia: Practice-based Research to Improve Outcomes (ESPRITO) - Using Artificial Intelligence to Measure Adherence to Oral Medication

NCT04046497 is registered in ClinicalTrials.gov with Northwell Health as lead sponsor.

NCT NCT04046497
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04046497 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early-phase Schizophrenia: Practice-based Research to Improve Outcomes (ESPRITO) - Using Artificial Intelligence to Measure Adherence to Oral Medication
Lead sponsor
Northwell Health
Phase
Phase 4
Overall status
Completed
Start date
November 20, 2020
Completion date
March 31, 2025
Enrollment
139 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

first episode psychosis